TriSalus Life Sciences, Inc. (TLSI) News
Track canonical SquawkNews coverage tagged to TLSI, TriSalus Life Sciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
TriSalus Life Sciences secures FDA 510(k) clearance for device
TriSalus Life Sciences said it received FDA 510(k) clearance for a new pressure-enabled drug delivery device; TLSI shares surged 26% to $6.21 after Tuesday’s close.
REGULATION | Sep 22, 2026, 09:24 PM UTC
L
TLSI: Innovative tumor therapy delivery, rapid growth, and new product launches drive future outlook
The company is driving innovation in solid tumor therapy with a unique catheter technology, expanding its sales force, and targeting new clinical indications. Strong revenue growth, improving margins, and a robust cash p
EARNINGS | Sep 14, 2026, 09:48 PM UTC
L
TLSI: Innovative tumor drug delivery drives rapid growth, with new products and clinical data set to expand market share
The company is driving innovation in tumor drug delivery with a unique catheter technology, expanding rapidly in the liver embolization market, and targeting new indications. Financial performance is strong, with robust
NEWS | Sep 14, 2026, 09:36 PM UTC
L
TriSalus Life Sciences initiated at buy by HC Wainwright
HC Wainwright & Co. initiated coverage on TriSalus Life Sciences with a buy rating.
EQUITY | Sep 09, 2026, 10:22 AM UTC
L
TriSalus Life Sciences Affirms FY2026 Sales Guidance of $54.000M-$57.000M vs $52.396M Est
TriSalus Life Sciences (NASDAQ: TLSI ) affirms FY2026 sales outlook from $54.000 million-$57.000 million to $54.000 million-$57.000 million vs $52.396 million estimate.
EARNINGS | Aug 06, 2026, 08:13 PM UTC